Drugs & Therapy Perspectives

, Volume 26, Issue 9, pp 15–18 | Cite as

Tumour necrosis factor (TNF) inhibitors are an effective option in the management of Crohn’s disease

Disease Management

References

  1. 1.
    Etchevers MJ, Ordás I, Ricart E. Optimizing the use of tumour necrosis factor inhibitors in Crohn’s disease: a practical approach. Drugs 2010; 70(2): 109–20PubMedCrossRefGoogle Scholar
  2. 2.
    Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn’s Colitis 2010 Feb; 4(1): 28–62CrossRefGoogle Scholar
  3. 3.
    Carter MJ, Lobo AJ, Travis SPL, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53Suppl. V: v1–16PubMedCrossRefGoogle Scholar
  4. 4.
    Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97(4): 947–53PubMedGoogle Scholar
  5. 5.
    Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133(2): 412–22PubMedCrossRefGoogle Scholar
  6. 6.
    British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 59. London: BMJ Publishing Group Ltd and RPS Publishing, 2010 MarGoogle Scholar
  7. 7.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130(2): 323–33PubMedCrossRefGoogle Scholar
  8. 8.
    Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56(9): 1232–9PubMedCrossRefGoogle Scholar
  9. 9.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132(1): 52–65PubMedCrossRefGoogle Scholar
  10. 10.
    Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146(12): 829–38PubMedGoogle Scholar
  11. 11.
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007; 357(3): 228–38PubMedCrossRefGoogle Scholar
  12. 12.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007; 357(3): 239–50PubMedCrossRefGoogle Scholar
  13. 13.
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1997; 337(15): 1029–35PubMedCrossRefGoogle Scholar
  14. 14.
    Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117(4): 761–9PubMedCrossRefGoogle Scholar
  15. 15.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541–9PubMedCrossRefGoogle Scholar
  16. 16.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340(18): 1398–405PubMedCrossRefGoogle Scholar
  17. 17.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350(9): 876–85PubMedCrossRefGoogle Scholar
  18. 18.
    Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009; 136(2): 441–50PubMedCrossRefGoogle Scholar
  19. 19.
    Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology 2007; 133(1): 312–39PubMedCrossRefGoogle Scholar
  20. 20.
    Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2008; (1): CD006893Google Scholar
  21. 21.
    Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104(1): 57–63PubMedCrossRefGoogle Scholar
  22. 22.
    D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008; 371(9613): 660–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Personalised recommendations